Full Press Release Details
Sinovac Biotech Announces Update on Nasdaq
BEIJING, November 30, 2017 /PRNewswire/ -- Sinovac Biotech Ltd.
(Nasdaq: SVA)(the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced
today that the Nasdaq Hearings Panel (the "Panel") granted the Company's request to extend the stay of suspension
in trading of the Company's common shares pending a hearing on January 11, 2018 and issuance of a final Panel decision. On
November 8, 2017, the Company appealed to the Panel the Nasdaq Staff's delisting determination dated November 1, 2017,and
the Panel has scheduled a hearing on January 11, 2018.
Sinovac Biotech Ltd. is a China-based biopharmaceutical
company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza,
H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps. The EV71 vaccine, an innovative vaccine developed by
Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first
company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination
campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government
stockpiling program. The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while
also exploring growth opportunities in international markets. The Company has exported select vaccines to over 10 countries in
Asia and South America. For more information, please visit the Company's website at www.sinovac.com.
Safe Harbor Statement
This announcement may include certain statements
that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the "safe
harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar statements. Forward-looking statements involve
risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements.
Sinovac Biotech Ltd.
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
Email: william.zima@icrinc.com